AAN Accepts Zinc-Cysteine Study Abstract

ANN ARBOR, Mich.Adeona Pharmaceuticals Inc. (AMEX: AEN) announced an abstract on the companys clinical trial of its zinc and cysteine-based product being evaluated in patients with Alzheimers disease and mild cognitive impairment (MCI) was accepted for presentation at the 2011 American Academy of Neurologys (AAN) Annual Meeting in Honolulu in April. Diana Pollock, M.D., lead principal investigator of the trial at Morton Plant Neuroscience Institute on the campus of Morton Plant Hospital, Tampa, Fla., is the first author on the abstract, "Clinical Trial Results of the First Controlled Clinical Trial of Zinc-Based Therapy for Alzheimer's Disease and Mild Cognitive Impairment." The randomized, double blind, placebo-controlled study included 60 patients taking the zinc-cysteine formulation or matching placebo daily for six months; the first six-month intervention is scheduled to conclude by the end of March 2011.

The company also announced it has adopted the name reaZin as the new trademark for its zinc and cysteine-based oral tablet, currently under development as a prescription medical food for the dietary management of Alzheimers disease and MCI. According to Adeona, reaZin is a homophone to the word reason," a high level cognitive function affected by Alzheimers disease; the Zin" root is also suggestive of one of the two major constituents of the proprietary, gastro-retentive, sustained-release tablet.

"The large gathering of neurologists at the American Academy of Neurology's 63rd Annual Meeting is an excellent scientific venue to present the pivotal clinical study results of our zinc and cysteine-based prescription medical food product candidate for Alzheimer's disease and mild cognitive impairment," said James S. Kuo, M.D., M.B.A., Adeona's chairman and CEO. "We are delighted that our clinical investigator has been accepted to present this important clinical data."